Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1. | Zendy

Ryan K. Shields | Zendy; Brian A. Potoski | Zendy; Ghady Haidar | Zendy; Binghua Hao | Zendy; Yohei Doi | Zendy; Liang Chen | Zendy; Ellen G. Press | Zendy; Barry N. Kreiswirth | Zendy; Cornelius J. Clancy | Zendy; M. Hong Nguyen | Zendy

Open Access

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

Author(s) -

Ryan K. Shields,

Brian A. Potoski,

Ghady Haidar,

Binghua Hao,

Yohei Doi,

Liang Chen,

Ellen G. Press,

Barry N. Kreiswirth,

Cornelius J. Clancy,

M. Hong Nguyen

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw636

Subject(s) - ceftazidime/avibactam , medicine , ceftazidime , enterobacteriaceae , avibactam , carbapenem resistant enterobacteriaceae , drug resistance , microbiology and biotechnology , biology , bacteria , escherichia coli , pseudomonas aeruginosa , biochemistry , genetics , gene

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research